向新陈代谢以增强瘤微环境中的免疫治疗
Xiao-Hui Liang1, Xin-Yi Chen1, Yue Yan1
1Shanghai Frontiers Science Center for Chinese Medicine Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Acta pharmacologica Sinica
|May 29, 2024
概括
癌细胞和免疫细胞重编程新陈代谢,影响抗瘤免疫力. 瘤微环境 (TME) 中的代谢竞争会导致营养缺乏和酸性,阻碍CD8+ T细胞的功能.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢过程中的代谢.
背景情况:
- 癌细胞和免疫细胞经历代谢重编程,影响瘤生长和免疫反应.
- 瘤微环境 (TME) 的代谢物包括乳酸,PGE2,FA,胆固醇,2-HG,腺和 kynurenine,这些代谢物会损害 CD8 + T 细胞的功能.
- 瘤和免疫细胞之间的代谢竞争导致TME的营养缺乏和酸化,抑制抗瘤免疫力.
研究的目的:
- 审查癌症中的代谢重编程及其对抗瘤免疫反应的影响.
- 突出代谢障碍在产生免疫抑制性TME中的作用.
- 讨论营养缺乏如何在TME内重新编程CD8+T细胞.
主要方法:
- 关于癌症代谢和瘤免疫学的文献综述.
- 分析关键代谢物及其对免疫细胞的影响.
- 针对瘤代谢和免疫反应的当前治疗策略的综合.
主要成果:
- 代谢重编程是癌症的标志,影响瘤细胞和免疫细胞.
- 在TME中的特定代谢物有助于T细胞功能障碍和免疫抑制.
- 代谢竞争和营养缺乏是阻碍抗瘤免疫反应的关键因素.
结论:
- 代谢重编程显著影响瘤发生和抗瘤免疫力.
- 向瘤代谢为增强癌症免疫治疗提供了潜在的治疗策略.
- 了解TME中的代谢相互作用对于未来的药物开发至关重要.
相关概念视频
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cytotoxic T Cells-mediated Immune Response
891
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
891


